Skip to main content
SpringerLink
Log in

A Review of the Pharmacological and Clinical Profile of Newer Atypical Antipsychotics as Treatments for Bipolar Disorder: Considerations for Use in Older Patients

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Bipolar disorder prevalence rates vary in the older adult population (defined as age ≥ 65 years), ranging from 1% in community dwellers to as high as 8–10% in hospital inpatients. Although older agents, including lithium and valproic acid, offer significant antimanic efficacy, as supported by a recent randomized controlled trial (RCT), there is growing interest in using atypical antipsychotics to treat bipolar disorder in older adults. Newer atypical antipsychotics are of interest based on their tolerability and efficacy in the general adult bipolar population. The aim of this review was to systematically examine efficacy and tolerability of newer atypical antipsychotics for older adult bipolar disorder (OABD). We conducted a systematic search utilizing the MEDLINE, EMBASE, PsycINFO and Cochrane Library electronic databases, with the aim of identifying all RCTs comparing newer atypical antipsychotics approved by the US FDA since 2002 (including brexpiprazole, cariprazine, lurasidone, iloperidone, asenapine, paliperidone, and aripiprazole) with placebo or another comparator, in the treatment of any phase of bipolar disorder (including mania, depression or mixed episodes while used as an acute or maintenance treatment) in older adults (> 65 years). We found no RCT data on any of the examined agents. Hence, we changed our search criteria to include studies with a lower age cut-off (≥ 55 years), as well as the inclusion of post hoc studies. Two post hoc studies on lurasidone suggest its reasonable safety and efficacy profile in the acute and maintenance treatment of OABD; however, there are no pharmacoeconomic data on the use of lurasidone in the treatment of OABD. Research data from open-label studies on oral asenapine and aripiprazole as add-on therapy suggest that these two agents are adequately tolerated and improved symptoms of depression and mania in OABD; hence, there is an urgent need to conduct RCTs on these two agents. Lastly, we found no studies for the treatment of OABD with brexpiprazole, cariprazine, iloperidone, or paliperidone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sajatovic M, Kessing LV. Bipolar disorder in the elderly. In: Yatham LN, Maj M, editors. Bipolar disorder: clinical and neurobiological foundations. Hoboken: Wiley; 2010. p. 488–98.

    Chapter  Google Scholar 

  2. Sajatovic M, Strejilevich SA, Gildengers AG, Dols A, Al Jurdi RK, Forester BP, et al. A report on older-age bipolar disorder from the International Society for Bipolar Disorders Task Force. Bipolar Disord. 2015;17(7):689–704.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Goodwin G, Haddad P, Ferrier I, Aronson J, Barnes T, Cipriani A, et al. Evidence-based guidelines for treating bipolar disorder revised third edition: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016;30(6):495–553.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97–170.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Hays JC, Krishnan KRR, George LK, Blazer DG. Age of first onset of bipolar disorder: Demographic, family history, and psychosocial correlates. Depress Anxiety. 1998;7(2):76–82.

    Article  CAS  PubMed  Google Scholar 

  6. Goldstein BI, Carnethon MR, Matthews KA, McIntyre RS, Miller GE, Raghuveer G, et al. major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2015;132(10):965–86.

    Article  PubMed  Google Scholar 

  7. Subramaniam H, Dennis MS, Byrne EJ. The role of vascular risk factors in late onset bipolar disorder. Int J Geriatr Psychiatry. 2007;22(8):733–7.

    Article  PubMed  Google Scholar 

  8. Kodesh A, Goldshtein I, Gelkopf M, Goren I, Chodick G, Shalev V. Epidemiology and comorbidity of severe mental illnesses in the community: Findings from a computerized mental health registry in a large Israeli health organization. Soc Psychiatry Psychiatr Epidemiol. 2012;47(11):1775–82.

    Article  PubMed  Google Scholar 

  9. Shulman KI, Herrmann N. Bipolar disorder in old age. Can Fam Physician. 1999;45:1229–37.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Roshanaei-Moghaddam B, Katon W. Premature mortality from general medical illnesses among persons with bipolar disorder: a review. Psychiatr Serv. 2009;60(2):147–56.

    Article  PubMed  Google Scholar 

  11. Vasudev A, Thomas A. “Bipolar disorder” in the elderly: what’s in a name? Maturitas. 2010;66:231–5.

    Article  PubMed  Google Scholar 

  12. Bowie MW, Slattum PW. Pharmacodynamics in older adults: a review. Am J Geriatr Pharmacother. 2007;5(3):263–303.

    Article  CAS  PubMed  Google Scholar 

  13. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Harada CN, Natelson Love MC, Triebel KL. Normal cognitive aging. Clin Geriatr Med. 2013;29:737–52.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Sajatovic M, Chen P. Geriatric bipolar disorder. Psychiatr Clin N Am. 2011;34:319–33.

    Article  Google Scholar 

  16. Al Jurdi RK, Marangell LB, Petersen NJ, Martinez M, Gyulai L, Sajatovic M. Prescription Patterns of psychotropic medication in the elderly compared to younger particioants who achieved a “recovered” status in the Systematic Treatment Rnhancement Program for Bipolar Disorder (STEP-BD). Am J Geriatr Psychiatry. 2008;16(11):922–33.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Young RC, Gyulai L, Mulsant BH, Flint A, Beyer JL, Shulman KI, et al. Pharmacotherapy of bipolar disorder in old age: review and recommendations. Am J Geriatr Psychiatry. 2004;12(4):342–57.

    Article  PubMed  Google Scholar 

  18. Gildengers AG, Mulsant BH, Begley AE, McShea M, Stack JA, Miller MD, et al. A pilot study of standardized treatment in geriatric bipolar disorder. Am J Geriatr Psychiatry. 2005;13(4):319–23.

    Article  PubMed  Google Scholar 

  19. Young RC, Mulsant BH, Sajatovic M, Gildengers AG, Gyulai L, Al Jurdi RK, et al. GERI-bd: A randomized double-blind controlled trial of lithium and divalproex in the treatment of mania in older patients with bipolar disorder. Am J Psychiatry. 2017;174(11):1086–93.

    Article  PubMed  Google Scholar 

  20. Chiu C-T, Wang Z, Hunsberger JG, Chuang D-M. Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev. 2013;65(1):105–42.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Acharya S, Bussel J. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol. 2000;22:62–5.

    Article  CAS  PubMed  Google Scholar 

  22. Lewis C, Deshpande A, Tesar GE, Dale R. Valproate-induced hyperammonemic encephalopathy: a brief review. Curr Med Res Opin. 2012;28(6):1039–42.

    Article  CAS  PubMed  Google Scholar 

  23. Anonymous. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(4):4–50.

    Google Scholar 

  24. Ruscin JM, Linnebur SA. Pharmacokinetics in the Elderly—Geriatrics—Merck Manuals Professional Edition. Merck Manual online. 2014. http://www.merckmanuals.com/professional/geriatrics/drug-therapy-in-the-elderly/pharmacokinetics-in-the-elderly#v1132432.

  25. Mohandas E, Rajmohan V. Lithium use in special populations. Indian J Psychiatry. 2007;49(3):211–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2003;57(1):6–14.

    Article  CAS  Google Scholar 

  27. Maeda K, Lerdrup L, Sugino H, Akazawa H, Amada N, McQuade RD, et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):605–14.

    Article  CAS  PubMed  Google Scholar 

  28. Citrome L. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic. What is the number needed to treat, number needed to harm and likelihood to be helped or harmed. Int J Clin Pract. 2015;69:978–97.

    Article  CAS  PubMed  Google Scholar 

  29. Brexpiprazole for schizophrenia. Aust Prescr. 40(5):197–8.

  30. Kiss B, Horvath A, Nemethy Z, Schmidt E, Laszlovszky I, Bugovics G, et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333(1):328–40.

    Article  CAS  PubMed  Google Scholar 

  31. Ágai-Csongor É, Domány G, Nógrádi K, Galambos J, Vágó I, Keser GM, et al. Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D 3/D 2 receptors. Bioorganic Med Chem Lett. 2012;22(10):3437–40.

    Article  CAS  Google Scholar 

  32. Durgam S, Starace A, Li D, Migliore R, Ruth A, Németh G, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord. 2015;17(1):63–75.

    Article  CAS  PubMed  Google Scholar 

  33. Calabrese JR, Keck PE, Starace A, Lu K, Ruth A, Laszlovszky I, et al. Efficacy and safety of low- and high-dose Cariprazine in acute and mixed mania associated with bipolar i disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2015;76(3):284–92.

    Article  PubMed  Google Scholar 

  34. Mattingly G, Anderson R. Cariprazine for schizophrenia and bipolar I disorder. Curr Psychiatry. 2016;15(2):34–9.

    Google Scholar 

  35. Werner F-M, Coveñas R. New developments in the management of schizophrenia and bipolar disorder: potential use of cariprazine. Ther Clin Risk Manag. 2015;11:1657–61.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Loebel A, Cucchiaro J, Silva R, Kroger H, Hsu J, Sarma K, et al. Lurasidone monotherapy in the treatment of bipolar i depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):160–8.

    Article  PubMed  Google Scholar 

  37. Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010;334(1):171–81.

    Article  CAS  PubMed  Google Scholar 

  38. Chiu Y-Y, Ereshefsky L, Preskorn SH, Poola N, Loebel A. Lurasidone drug-drug interaction studies: a comprehensive review. Drug Metabol Drug Interact. 2014;29(3):191–202.

    Article  CAS  PubMed  Google Scholar 

  39. Latuda. Latuda (Lurasidone): Highlights of prescribing information.

  40. Sajatovic M, Forester BP, Tsai J, Kroger H, Pikalov A, Cucchiaro J, et al. Efficacy of lurasidone in adults aged 55 years and older with bipolar depression: post hoc analysis of 2 double-blind, placebo-controlled studies. J Clin Psychiatry. 2013;2016(2012):1–8.

    Google Scholar 

  41. Forester BP, Sajatovic M, Tsai J, Pikalov A, Cucchiaro J, Loebel A. Safety and effectiveness of long-term treatment with Lurasidone in older adults with bipolar depression: post-hoc analysis of a 6-month, open-label study. Am J Geriatr Psychiatry. 2018;26(2):150–9.

    Article  PubMed  Google Scholar 

  42. FDA, Center for Drug Evaluation and Research. Granisetron: highlights of prescribing information.

  43. Crabtree BL, Montgomery J. Iloperidone for the management of adults with schizophrenia. Clin Ther. 2011;33(3):330–45.

    Article  CAS  PubMed  Google Scholar 

  44. Wang S-M, Han C, Lee S-J, Patkar AA, Masand PS, Pae C-U. Asenapine, blonanserin, iloperidone, lurasidone, and sertindole. Clin Neuropharmacol. 2013;36(6):223–38.

    Article  CAS  PubMed  Google Scholar 

  45. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry. 1999;6060(10):5–14.

    Google Scholar 

  46. Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology. 2001;25(6):904–14.

    Article  CAS  PubMed  Google Scholar 

  47. Sedek G, Wolfgang C. Iloperidone is well tolerated by subjects with renal or hepatic impairment in single-dose clinical pharmacokinetic studies. In: American Psychiatric Association Annual Meeting; 19–24 May 2007: San Diego, CA.

  48. Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of Iloperidone in the Treatment of Schizophrenia. J Clin Psychopharmacol. 2008;28(Suppl. 1):S4–11.

    Article  CAS  PubMed  Google Scholar 

  49. Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safety profile of iloperidone. J Clin Psychopharmacol. 2008;28(Suppl. 1):S12–9.

    Article  CAS  Google Scholar 

  50. Bobo WV. Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013;6(1):61–91.

    Article  CAS  PubMed  Google Scholar 

  51. Andrade C. Stahl’s Essential psychopharmacology: neuroscientific basis and practical applications. Mens Sana monographs, vol. 8. 4th ed. Barcelona, Cambridge: University Press; 2010. p. 146.

    Google Scholar 

  52. Pratts M, Citrome L, Grant W, Leso L, Opler LA. A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation. Acta Psychiatr Scand. 2014;130(1):61–8.

    Article  CAS  PubMed  Google Scholar 

  53. Janssen. Product monograph: asenapine. New York: Janssen; 2003. p. 1–52.

    Google Scholar 

  54. Dubovsky SL, Frobose C, Phiri P, Panagides J. Short-term tolerability, safety, and pharmacokinetic profile of asenapine in older patients with psychosis. Schizophr Res. 2010;117(2–3):263–4.

    Article  Google Scholar 

  55. Corena-McLeod M. Comparative pharmacology of risperidone and paliperidone. Drugs R D. 2015;15(2):163–74.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  56. Janicak PG, Winans E. Paliperidone ER: a review of the clinical trial data. Neuropsychiatr Dis Treat. 2007;3(6):869–97.

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Knegtering R, Baselmans P, Castelein S, Bosker F, Bruggeman R, Van Den Bosch RJ. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry. 2005;162(5):1010–2.

    Article  PubMed  Google Scholar 

  58. Skopek M, Manoj P. Hyperprolactinaemia during treatment with paliperidone. Australas Psychiatry. 2010;18(3):261–3.

    Article  PubMed  Google Scholar 

  59. Vermeir M, Naessens I, Remmerie B, Mannens G, Hendrickx J, Sterkens P, et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos. 2008;36(4):769–79.

    Article  CAS  PubMed  Google Scholar 

  60. Berwaerts J, Lane R, Nuamah IF, Lim P, Remmerie B, Hough DW. Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study. J Affect Disord. 2011;129(1–3):252–60.

    Article  CAS  PubMed  Google Scholar 

  61. Berwaerts J, Melkote R, Nuamah I, Lim P. A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar i disorder after an acute manic or mixed episode. J Affect Disord. 2012;138(3):247–58.

    Article  CAS  PubMed  Google Scholar 

  62. FDA Label. Aripiprazole abilify FDA-label. Interactions. 1998;50:1–25. http://pi.lilly.com/us/zyprexa-pi.pdf.

  63. Shirley M, Perry CM. Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia. Drugs. 2014;74(10):1097–110.

    Article  CAS  PubMed  Google Scholar 

  64. H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co. L. Abilify Maintena® (aripiprazole) for extended-release injectable suspension approved by the US FDA for maintenance monotherapy treatment of bipolar I disorder. Lundbeck; 2017.

  65. Leucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–62.

    Article  CAS  Google Scholar 

  66. Sajatovic M, Coconcea N, Ignacio RV, Blow FC, Hays RW, Cassidy KA, et al. Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial. J Clin Psychiatry. 2008;69(1):41–6.

    Article  CAS  PubMed  Google Scholar 

  67. Lenze EJ, Mulsant BH, Blumberger DM, Karp JF, Newcomer JW, Anderson SJ, et al. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(10011):2404–12.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Geriatric Psychiatry, Department of Psychiatry, Western University, London, ON, Canada

    Akshya Vasudev, Sumit Chaudhari & Rickinder Sethi

  2. Western Libraries, Western University, London, ON, Canada

    Rachel M. Sandieson

  3. Division of Geriatric Psychiatry, McLean Hospital, Belmont, MA, USA

    Brent P. Forester

  4. Department of Psychiatry, Harvard Medical School, Boston, MA, USA

    Brent P. Forester

  5. Department of Medicine, Western University, London, ON, Canada

    Akshya Vasudev

  6. Department of Pharmacy, London Health Sciences Centre, A2-607, Victoria Hospital, 800 Commissioners Road East, London, ON, N6A 5W9, Canada

    Rachel Fu

Authors
  1. Akshya Vasudev
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sumit Chaudhari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rickinder Sethi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rachel Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rachel M. Sandieson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Brent P. Forester
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Akshya Vasudev.

Ethics declarations

Funding

No funding was received for the preparation of this manuscript.

Conflicts of interest

Akshya Vasudev, Sumit Chaudhari, Rickinder Sethi, Rachel Fu, Rachel M. Sandieson and Brent P. Forester have no conflicts of interest to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vasudev, A., Chaudhari, S., Sethi, R. et al. A Review of the Pharmacological and Clinical Profile of Newer Atypical Antipsychotics as Treatments for Bipolar Disorder: Considerations for Use in Older Patients. Drugs Aging 35, 887–895 (2018). https://doi.org/10.1007/s40266-018-0579-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-018-0579-6

Search

Navigation